Cheers buddy. It's late here and I'm still finishing my proper work.
England has begun to emerge out of Covid lock-down (finally as vaccines stop deaths and hospitalisations). It's clear that there is a lot of focus on licensure, manufacturing and clinical traction over here for the company. Assuming that no variants emerge which drive the Prime Minister to slow / reverse our roadmap out, the company should have a lot more room to move.
I've found it helpful to consider that their all-in cash burn is about 32m usd to cover operations. Much of that amount is going towards clinical trials expense in R&D and even some into capital equipment pre-payments (1m usd worth). At a Gross Margin of 65% (I'm guessing) in the new UK facility, they'd only need to treat about 200-225 patients p.a. to fully cover their cash burn (at 250k usd per patient).
News 
Market Data 
Discover 
